Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, Global Outlook and Forecast 2024-2031

Report ID: 1134131 | Published Date: Jan 2025 | No. of Page: 67 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Overall Market Size
    2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2021 VS 2028
    2.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
    3.2 Top Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Ranked by Revenue
    3.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies
    3.4 Top 3 and Top 5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
        3.6.1 List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies
        3.6.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Markets, 2021 & 2028
        4.1.2 Intravenous
        4.1.3 Oral
        4.1.4 Subcutaneous
        4.1.5 Others
    4.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
        4.2.1 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022
        4.2.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028
        4.2.3 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2021 & 2028
        5.1.2 Hospital
        5.1.3 Clinic
        5.1.4 Others
    5.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
        5.2.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022
        5.2.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028
        5.2.3 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2021 & 2028
    6.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts
        6.2.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022
        6.2.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028
        6.2.3 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
        6.3.2 US Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.3.3 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.3.4 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
        6.4.2 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.4.3 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.4.4 U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.4.5 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.4.6 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.4.7 Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.4.8 Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
        6.5.2 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.5.3 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.5.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.5.5 Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.5.6 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
        6.6.2 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.6.3 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028
        6.7.2 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.7.3 Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.7.4 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
        6.7.5 UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028
7 Players Profiles
    7.1 F. Hoffmann-La Roche Ltd
        7.1.1 F. Hoffmann-La Roche Ltd Corporate Summary
        7.1.2 F. Hoffmann-La Roche Ltd Business Overview
        7.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.1.4 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.1.5 F. Hoffmann-La Roche Ltd Key News
    7.2 Alexion Pharmaceuticals
        7.2.1 Alexion Pharmaceuticals Corporate Summary
        7.2.2 Alexion Pharmaceuticals Business Overview
        7.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.2.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.2.5 Alexion Pharmaceuticals Key News
    7.3 RemeGen
        7.3.1 RemeGen Corporate Summary
        7.3.2 RemeGen Business Overview
        7.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.3.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.3.5 RemeGen Key News
    7.4 Nihon Pharmaceutical
        7.4.1 Nihon Pharmaceutical Corporate Summary
        7.4.2 Nihon Pharmaceutical Business Overview
        7.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.4.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.4.5 Nihon Pharmaceutical Key News
    7.5 Harbour BioMed
        7.5.1 Harbour BioMed Corporate Summary
        7.5.2 Harbour BioMed Business Overview
        7.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.5.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.5.5 Harbour BioMed Key News
    7.6 Lundbeck
        7.6.1 Lundbeck Corporate Summary
        7.6.2 Lundbeck Business Overview
        7.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.6.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.6.5 Lundbeck Key News
    7.7 Bionure
        7.7.1 Bionure Corporate Summary
        7.7.2 Bionure Business Overview
        7.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.7.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.7.5 Bionure Key News
    7.8 Opexa Therapeutics
        7.8.1 Opexa Therapeutics Corporate Summary
        7.8.2 Opexa Therapeutics Business Overview
        7.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.8.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.8.5 Opexa Therapeutics Key News
    7.9 TG Therapeutics
        7.9.1 TG Therapeutics Corporate Summary
        7.9.2 TG Therapeutics Business Overview
        7.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.9.5 TG Therapeutics Key News
    7.10 Bio-Thera Solutions
        7.10.1 Bio-Thera Solutions Corporate Summary
        7.10.2 Bio-Thera Solutions Business Overview
        7.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.10.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.10.5 Bio-Thera Solutions Key News
    7.11 Boston Pharmaceuticals
        7.11.1 Boston Pharmaceuticals Corporate Summary
        7.11.2 Boston Pharmaceuticals Business Overview
        7.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.11.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.11.5 Boston Pharmaceuticals Key News
    7.12 Cour Pharmaceutical
        7.12.1 Cour Pharmaceutical Corporate Summary
        7.12.2 Cour Pharmaceutical Business Overview
        7.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
        7.12.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
        7.12.5 Cour Pharmaceutical Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunities & Trends in Global Market
    Table 2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers in Global Market
    Table 3. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints in Global Market
    Table 4. Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Global Market
    Table 5. Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type
    Table 9. List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2023-2028
    Table 30. F. Hoffmann-La Roche Ltd Corporate Summary
    Table 31. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 32. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 33. Alexion Pharmaceuticals Corporate Summary
    Table 34. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 35. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 36. RemeGen Corporate Summary
    Table 37. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 38. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 39. Nihon Pharmaceutical Corporate Summary
    Table 40. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 41. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 42. Harbour BioMed Corporate Summary
    Table 43. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 44. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 45. Lundbeck Corporate Summary
    Table 46. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 47. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 48. Bionure Corporate Summary
    Table 49. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 50. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 51. Opexa Therapeutics Corporate Summary
    Table 52. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 53. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 54. TG Therapeutics Corporate Summary
    Table 55. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 56. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 57. Bio-Thera Solutions Corporate Summary
    Table 58. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 59. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 60. Boston Pharmaceuticals Corporate Summary
    Table 61. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 62. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
    Table 63. Cour Pharmaceutical Corporate Summary
    Table 64. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings
    Table 65. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Type in 2021
    Figure 2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Application in 2021
    Figure 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2021
    Figure 8. By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 12. US Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 16. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 17. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 24. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 28. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 30. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
    Figure 33. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US$, Mn), 2017-2028
    Figure 37. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 47. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 48. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
67
Frequently Asked Questions
Neuromyelitis Optica Spectrum Disorder Market In Global report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neuromyelitis Optica Spectrum Disorder Market In Global report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neuromyelitis Optica Spectrum Disorder Market In Global report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports